Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2017-07-16 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
关于深圳证券交易所《关于对三诺生物传感股份有限公司的重组问询函》的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry from the Shenzhen Stock Exchange regarding a restructuring involving SanNuo Biological Sensor Co., Ltd. It discusses in depth the contingent consideration (or contingent payments) related to the acquisition of PTS, including sales performance, product development, FDA approval challenges, valuation methods, and financial performance analysis. The document includes extensive financial and operational analysis, valuation discussions, and management's explanations about profitability and strategic plans. It is clearly related to a corporate restructuring transaction involving acquisition and financing, with detailed financial and valuation disclosures. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. It is a regulatory response document related to a major asset restructuring and acquisition transaction, including valuation and financial analysis. This fits best under the category of Capital/Financing Update (CAP), as it provides updates and detailed information on the financing and restructuring transaction, including contingent consideration and valuation analysis.
2017-07-16 Chinese
关于公司股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of trading of the company's stock after a suspension due to a major asset restructuring. It references prior announcements and regulatory filings related to the asset restructuring and the stock suspension. The document does not contain financial statements, detailed financial data, or comprehensive report content. It primarily serves as a notice about the stock resumption date and related procedural updates. The document length is only 1295 characters, which is quite short and fits the pattern of an announcement rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2017-07-16 Chinese
中信证券股份有限公司关于公司发行股份购买资产并募集配套资金之独立财务顾问报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report (Revised)" issued by CITIC Securities Co., Ltd. regarding the issuance of shares to purchase assets and raise supporting funds by SanNuo Biological Sensor Co., Ltd. The content includes detailed sections such as transaction overview, asset evaluation, legal opinions, financial data, and compliance with regulatory requirements. It is a comprehensive advisory report related to a major asset restructuring transaction involving issuance of shares and capital raising. The document is lengthy (15,000 characters) and contains substantive financial and legal analysis, not merely an announcement or certification. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through issuance of shares to purchase assets and raise funds. It is not an Annual Report, Audit Report, or Regulatory Filing, nor is it a simple announcement or proxy material. Therefore, the appropriate classification is CAP with high confidence.
2017-07-16 Chinese
北京国枫律师事务所关于公司发行股份购买资产并募集配套资金的补充法律意见书之一
Capital/Financing Update Classification · 95% confidence The document is a supplementary legal opinion letter issued by Beijing Grandway Law Offices regarding a major asset restructuring involving SanNuo Biological Sensor Co., Ltd. It specifically addresses legal matters related to the issuance of shares to purchase assets and the raising of supporting funds. The document references a '重组报告书' (Restructuring Report) and discusses regulatory compliance, patent licensing, product registration, and procedural requirements for the transaction. It is a detailed legal opinion supporting a capital/financing transaction rather than a financial report, earnings release, or management discussion. The document is not an announcement of a report but a substantive legal opinion related to a financing and asset purchase transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is not a brief announcement or certification but a full legal opinion letter.
2017-07-16 Chinese
发行股份购买资产并募集配套资金报告书（草案修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a report on issuance of shares to purchase assets and raise supporting funds by SanNuo Bio-sensing Co., Ltd. It includes detailed sections such as transaction overview, parties involved, asset evaluation, financial data, risk factors, compliance analysis, and management discussion and analysis. The content is comprehensive and substantive, covering a major asset restructuring transaction with financial and legal details. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers company fundraising and capital structure changes. The document is not a simple announcement or a brief summary but a full report on the transaction and financing. Therefore, the appropriate classification is CAP with high confidence.
2017-07-16 Chinese
发行股份购买资产并募集配套资金报告书（草案）摘要（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "三诺生物传感股份有限公司 发行股份购买资产并募集配套资金 报告书（草案）摘要（修订稿）" which translates to a report on issuance of shares to purchase assets and raise supporting funds. It includes extensive sections such as transaction overview, asset evaluation, financial data, risk disclosures, and legal compliance. The content focuses on a major asset restructuring involving issuance of shares to purchase a 64.98% stake in another company and raising funds through private placement. The document references regulatory frameworks related to major asset restructuring and securities issuance, and includes audited financial data and valuation reports. This is characteristic of a Capital/Financing Update filing, as it details fundraising activities and capital structure changes related to a significant asset acquisition. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or proxy statement. The length (15,000 characters) and detailed financial and transaction information confirm it is a substantive report, not just an announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-07-16 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.